About us
Focusing on breakthrough innovation that benefits patients
We are a pioneering, commercial-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infectious and autoimmune diseases.
Our initial therapeutic focus is in oncology, where pivotal clinical trials are currently underway for our lead program, tebentafusp (IMCgp100), as a potential treatment for metastatic uveal melanoma, a rare form of eye cancer.
We also have a robust pipeline of programs spanning a broad range of cancer indications, as well as infectious and autoimmune diseases.
Video
ImmTAC® molecules in action
Our story
Our vision
At Immunocore, we believe we are TCR pioneers with a passion to transform patients' lives and a goal to deliver new medicines. We will implement this bold vision by following our values.
Our values
We lead with science to benefit patients
We work together to set clear priorities and objectives aligned to the organisation’s goals, to create an environment that maximises individual contributions that will benefit patients.
We are entrepreneurial
We are drawn to opportunities to seek out key areas of improvement; we ask questions, voice opinions and take initiative to get things done.
We value diversity to drive innovation
We value and listen to all views and opinions. Our success is dependent on pushing boundaries, utilizing diverse skills and approaches to foster creative thinking.
We respect and trust each other
We respect and trust each other with good intentions and are consistent and fair as to how we treat others. We foster transparent and frequent communication.
We act with integrity
We act with integrity taking responsibility for our actions and challenge actions or decisions we believe to be wrong. We take decisions to improve the success of the organisation.